In summary, our results demonstrate that the combination of berberine and evodiamine effectively reduces body weight and fat mass, improves lipid and glucose metabolism, and enhances insulin sensitivity in vivo, highlighting the potential of BBE as a therapeutic agent for obesity and related metabolic disorders. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.